Tumoral drug metabolism: Overview and its implications for cancer therapy

Journal of Clinical Oncology

Volumn 23, Issue 1, 2005, Pages 205-229

  Michael, M ^a   Doherty, M M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; BETA GLUCURONIDASE; CAPECITABINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; DRUG METABOLIZING ENZYME; FLUTAMIDE; GLUCORONIDE TRANSFERASE; GLUTATHIONE TRANSFERASE; IFOSFAMIDE; IMATINIB; MELPHALAN; MITOMYCIN C; OXIDOREDUCTASE; PACLITAXEL; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RETINOIC ACID; SULFATASE; SULFOTRANSFERASE; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL LINE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; DRUG ACTIVITY; DRUG METABOLISM; DRUG TARGETING; ENZYME ACTIVITY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MODEL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; XENOGRAFT; ANIMAL; BIOTRANSFORMATION; DRUG DESIGN; ENZYMOLOGY; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 16644379769     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.120     Document Type: Article

References (258)

1. Elsayad YA, Sausville EA: Selected novel anticancer treatments targeting cell signalling proteins. Oncologist 6:517-537, 2001
2. Rendic S: Human cytochrome P450 enzymes: Status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 29:413-580, 1997
3. Rendic, S: Human P450 metabolism database, http://www.gentest.com/ human_p450_ databse
4. Tukey RH, Strassburg CP: Genetic multiplicity of the human UDP-Glucuronosyl-transferases and regulation in the gastrointestinal tract. Mol Pharm 59:405-414, 2001
5. Desai AA, Innocenti F, Ratain MJ: UGT pharmacogenomics: Implications for cancer risk and cancer therapeutics. Pharmacogenomics 13:517-523, 2003
6. Townsend DM, Tew KD: The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22:7369-7375, 2003
7. El Mouelhi M, Didolkar MS, Elias G, et al: Hepatic drug-metabolising enzymes in primary and secondary tumours of human liver. Cancer Res 47:460-466, 1987
8. Guengerich FP: Roles of cytochrome P450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res 48:2946-2954, 1988
9. Guengerich FP, Turvey CG: Comparison of levels of several human microsomal cytochrome P450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharm Exp Ther 256:1189-1193, 1991
10. Patterson LH, Murray GI: Tumour cytochrome P450 and drug activation. Curr Pharm Des 8:1335-1347, 2002
11. Ingelman-Sundberb M: Genetic variability in susceptibility and response to toxicants. Toxicol Lett 120:259-268, 2001
12. Sekine I, Saijo N: Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann Oncol 12:1515-1525, 2001
13. Mannervik B: The isoenzymes of glutathione-s-transferase. Adv Enzymol 57:357-417, 1985
14. Ambrosone CB, Sweeney C, Coles BF, et al: Polymorphisms in glutathione S-transferases (GSTMI and GSTT1) and survival after treatment for breast caner. Cancer Res 61:7130-7135, 2001
15. Strassburg CP, Strassburg A, Nguyen N, et al: Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. Biochem J 338:489-498, 1999
16. Gagne J-F, Montminy V, Belanger P, et al: Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617, 2002
17. Rekha GK, Sladek NE: Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics. Cancer Chemother Pharmacol 40:215-224, 1997
18. Murray GI: The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol 192:419-426, 2000
19. Suzuki T, Nisho K, Tanabe S: The MRP family and anticancer drug metabolism. Curr Drug Metab, 2:367-377, 2001
20. von Bubnoff N, Schneller F, Peschel C, et al: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to ST1571: A prospective study. Lancet 359:487-491, 2002
21. Kinsella AR, Smith D: Tumor resistance to antimetabolites. Gen Pharm 30:623-626, 1998
22. Fojo T: Cancer, DNA repair mechanisms, and resistance to chemotherapy. J Natl Cancer Inst 93:1434-1436, 2001
23. Rochat B, Morsman JM, Murray GI, et al: Human CYP1B1 and anticancer agent metabolism: Mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296:537-541, 2001
24. Schuler J, Cassidy J, Dumont E, et al: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291-297, 2000
25. Chen L, Yu LJ, Waxman DJ: Potentiation of cytochrome P450/ cyclophosphamide-based cancer gene therapy by coexpression of the p450 reductase gene. Cancer Res 57:4830-4837, 1997
26. Huang Z, Waxman DJ: Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors. Cancer Gene Ther 8:450-458, 2001
27. Niculescu-Duvaz I, Cooper RG, Stribbling SM, et al: Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Opin Mol Ther 1:480-486, 1999
28. Waxman DJ, Chen L, Hecht JED, et al: Cytochrome P450-based cancer gene therapy: Recent advances and future prospects. Drug Metab Rev 31:503-522, 1999
29. Wang S-M, Chern J-W, Yeh M-Y, et al: Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res 52:4484-4491, 1992
30. Tannock IF, Lee CM, Tunggal JK, et al: Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 8:878-884, 2002
31. Brown JM, Giaccia AJ: The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416, 1998
32. Jounaidi Y, Waxman DJ: Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res 60:3761-3769, 2000
33. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48-58, 2002
34. Kruh GD, Belinsky MG: The MRP family of drug efflux pumps. Oncogene 22:7537-7552, 2003
35. Borst P, Evers R, Kool M, et al: A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302, 2000
36. Guo Y, Kotova E, Chen ZS, et al: MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′- phosphonylmethoxyethyl)adenine. J Biol Chem 278:29509-29514, 2003
37. Doyle LA, Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358, 2003
38. Mossink MH, van Zon A, Scheper RJ, et al: Vaults: A ribonucleoprotein particle involved in drug resistance? Oncogene 22:7458-7467, 2003
39. Wacher VJ, Silverman JA, Zhang Y, et al: Role of P-glycoprotein and cytochrome P4503A in limiting oral absorption of peptides and peptidomimetic. J Pharm Sci 87:1322-1330, 1998
40. Kim RB, Wandel C, Leake B, et al: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16:408-414, 1999
41. Lan LB, Dalton JT, Schuetz EG: Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol 58:863-869, 2000
42. Xie W, Barwick JL, Downes M, et al: Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435-439, 2000
43. Synold TW, Dussault I, Forman BM: The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590, 2001
44. Dotzlaw H, Leygue E, Watson P, et al: The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin Cancer Res 5:2103-2107, 1999
45. Pfrunder A, Gutmann H, Beglinger C, et al: Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines. J Pharm Pharmacol 55:59-66, 2003
46. Takami N, Sakamoto H, Yamamoto T: Steroid and xenobiotic receptor (SXR) is a key system for the acquisition of cisplatin resistance in endometrial cancer cells. J Int Med Res 31:59-68, 2003
47. Murray GI, Taylor MC, McFadyen MC, et al: Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57:3026-3031, 1997
48. Albin N, Massaad L, Toussaint C, et al: Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res 53:3541-3546, 1993
49. Huang Z, Fasco MJ, Figge HL, et al: Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 24:899-905, 1996
50. Sladek NE, Kollander R, Sreerama L, et al: Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: A retrospective study-Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 49:309-321, 2002
51. Sreerama L, Sladek N: Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants: Rational individualization of cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 47:255-262, 2001
52. Brockdorff BL, Skouv J, Reiter BE, et al: Increased expression of cytochrome P450 1A1 and 1B1 genes in anti-oestrogen-resistant human breast cancer cell lines. Int J Cancer 88:902-906, 2000
53. Smith G, Harrison DJ, East N, et al: Regulation of cytochrome P450 gene expression in human colon and breast xenografts. Br J Cancer 68:57-63, 1993
54. Liehr JG, Ricci MJ: 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci 93:3294-3296, 1996
55. Horiguchi J, Takai H, Koibuchi Y, et al: Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. Br J Cancer 86:222-225, 2002
56. Marin A, Lopez de Cerain A, Hamilton E, et al: DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br J Cancer 76:923-929, 1997
57. Nakamura T, Sakaeda T, Ohmoto N, et al: Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cells human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab Dispos 30:4-6, 2002
58. Murray GI, Taylor MC, Burke M: D, et al: Enhanced expression of cytochrome P450 in stomach cancer. Br J Cancer 77:1040-1044, 1998
59. Massaad L, de Waziers I, Ribrag V, et al: Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolising enzyme systems. Cancer Res 52:6567-6575, 1992
60. Collie-Duguid E, Johnston SJ, Boyce L, et al: Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. Int J Cancer 94:297-301, 2001
61. Johnston SJ, Ridge SA, Cassidy J, et al: Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res 5:2566-2570, 1999
62. Czerwinski M, McLemore TL, Gelboin HV, et al: Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors. Cancer Res 54:1085-1091, 1994
63. Fujitaka K, Oguri T, Isobe T, et al: Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. Cancer Chemother Pharmacol 48:42-46, 2001
64. Troussaint C, Albin N, Massaad L, et al: Main drug-and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues. Cancer Res 53:4608-4612, 1993
65. Nhamburo PT, Kimura S, McBride OW, et al: The human CYP2F gene subfamily: Identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression, and chromosome mapping. Biochemistry 29:5491-5499, 1990
66. Higashiyama M, Kodama K, Yokouchi H, et al: Thymidylate synthetase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: Relationship with in vitro sensitivity to 5-fluorouracil. Lung Cancer 34:407-416, 2001
67. Ribrag V, Massaad L, Janot F, et al: Main drug-metabolizing enzyme systems in human non-Hodgkin's lymphomas sensitive or resistant to chemotherapy. Leuk Lymphoma 18:303-310, 1995
68. Nagai F, Hiyoshi Y, Sugimachi K, et al: Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. Biol Pharm Bull 25:383-385, 2002
69. Mungikar AM, Zingde SM, Advabr SH, et al: Mixed function oxidase enzymes in human normal granulocytes and chronic myeloid leukemia cells, I: Detection and Estimation. Biochem Med 30:181-187, 1983
70. Xie HJ, Lundgren S, Broberg U, et al: Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. Eur J Pharmacol 449:197-205, 2002
71. Bhagwat SV, Boyd MR, Ravindranath V: Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria. Biochem Pharmacol 59:573-582, 2000
72. Iscan M, Klaavuniemi T, Coban T, et al: The expression of P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Res Treat 70:47-54, 2001
73. Nishimura M, Yaguti H, Yoshitsugu H, et al: Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123:369-375, 2003
74. Nishimura M, Yoshitsugu H, Naito S, et al: Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 122:339-361, 2002
75. Stam RW, den Boer ML, Meijerink JP, et al: Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 101:1270-1276, 2003
76. Nebert DW, Gonzalez FJ: P450 genes: Structure, evolution and regulation. Annu Rev Biochem 56:945-993, 1987
77. Crewe HK, Notley LM, Wunsch RM, et al: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: Formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869-874, 2002
78. Gonzalez FJ, Gelboin HV: Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26:165-183, 1994
79. McFadyen MC, McLeod HL, Jackson FC, et al: Cytochrome P450 CYP1B1 protein expression: A novel mechanism of anticancer drug resistance. Biochem Pharmacol 62:207-212, 2001
80. Chang GWM, Kam PCA: The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anesthesia 54:42-50, 1999
81. Roy P, Yu LJ, Crespi CL, et al: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655-666, 1999
82. Schmidt R, Baumann F, Knupfer H, et al: CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. Br J Cancer 90:911-916, 2004
83. El-Rayes BF, Ali S, Heilbrun LK, et al: Cytochrome p450 and glutathione transferase expression in human breast cancer. Clin Cancer Res 9:1705-1709, 2003
84. Lechevrel M, Casson AG, Wolf CR, et al: Characterization of cytochrome P450 expression in human oesophageal mucosa. Carcinogenesis 20:243-248, 1999
85. Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355, 2001
86. Rahman A, Korzekwa KR, Grogan J, et al: Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546, 1994
87. Dai D, Zeldin DC, Blaisdell JA, et al: Polymorphisms in human CYP2C8 decrease: Metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607, 2001
88. Monsarrat B, Chatelut E, Royer I, et al: Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 26:229-233, 1998
89. Ando Y, Fuse E, Figg WD: Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964-1973, 2002
90. Ando Y, Price DK, Dahut WL, et al: Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther 1:669-673, 2002
91. Martinez C, Garcia-Martin E, Pizarro RM, et al: Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: Implications for drug therapy. Br J Cancer 87:681-686, 2002
92. Lamba JK, Lin YS, Schuetz EG, et al: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294, 2002
93. van Schaik RH, van der Heiden IP, van den Anker JN, et al: CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668-1671, 2002
94. Fukuen S, Fukuda T, Maune H, et al: Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmagenomics 12:331-334, 2002
95. Murray GI, McFadyen MC, Mitchell RT, et al: Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 79:1836-1842, 1999
96. Finnstrom N, Bjelfman C, Soderstrom TG, et al: Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur J Clin Invest 31:880-886, 2001
97. Kolesar JM, Breunig A, Miller J, et al: CYP3A5*3 and CYP3A4*1B polymorphisms are associated and more frequent in NSCLC tumors than in normal volunteers. Proc Am Soc Clin Oncol 23:131, 2004 (abstr 2016)
98. King CD, Rios GR, Green MD, et al: UDP-glucuronyltransferases. Curr Drug Metab 1:143-161, 2000
99. Turgeon D, Carrier JS, Levesque E, et al: Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787, 2001
100. Strassburg CP, Nyguyen N, Manns MP, et al: Polymorphic expression the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol 54:647-654, 1998
101. Strassburg CP, Manns MP, Tukey RH: Differential downregualtion of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 57:2979-2985, 1997
102. Ullrich D, Munzel PA, Beck-Gshaidmeier S, et al: Drug metabolizing enzymes in pharyngeal mucosa and on roopharyngeal cancer tissue. Biochem Pharmacol 54:1159-1162, 1997
103. Gestl SA, Green MD, Shearer DA, et al: Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers. Am J Pathol 160:1467-1479, 2002
104. Belanger G, Beaulieu M, Marcotte B, et al: Expression of transcripts encoding steroid UDP-glucuronosyltransferases in human prostate hyperplastic tissue and the LNCaP cell line. Mol Cell Endocrinol 113:165-173, 1995
105. Levesque E, Beaulieu M, Guillemette C, et al: Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line. Endocrinology 139:2375-2381, 1998
106. Guillemette C, Levesque E, Beaulieu M, et al: Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. Endocrinology 138:2998-3005, 1997
107. Watson MA, Stewart RK, Smith GB, et al: Human glutathione S-transferase P1 polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19:275-280, 1998
108. London SJ, Yuan JM, Chung FL, et al: Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: A prospective study of men in Shanghai, China. Lancet 356:724-729, 2000
109. Howells RE, Dhar KK, Hoban PR, et al: Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 overexpression, and outcome in epithelial ovarian cancer. Int J Gynecol Cancer 14:242-250, 2004
110. Moorghen M, Cairns J, Forrester LM, et al: Enhanced expression of glutathione S-transferases in colorectal carcinoma compared to non-neoplastic mucosa. Carcinogenesis 12:13-17, 1991
111. Mulder TP, Verspaget HW, Sier CF, et al: Glutathione S-transferase pi in colorectal tumors is predictive for overall survival. Cancer Res 55:2696-2702, 1995
112. Koomagi R, Stammler G, Manegold C, et al: Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer. Cancer Lett 110:129-136, 1996
113. Okuyama T, Maehara Y, Endo K, et al: Expression of glutathione S-transferase-π- and sensitivity of human gastric cancer cells to cisplatin. Cancer 74:1230-1236, 1994
114. Sakakura C, Hagiwara A, Nakanishi M, et al: Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites. Br J Cancer 87:1153-1161, 2002
115. Skelly JV, Knox RJ, Jenkins TC: Aerobic nitroreduction by flavoproteins: Enzyme structure, mechanisms and role in cancer chemotherapy. Mini Rev Med Chem 1:293-306, 2001
116. Gutierrez PL: The role of NAD(P)H oxidoreductase (DT-diaphorase) in the bioactivation of quinone-containing antitumor agents: A review. Free Radic Biol Med 29:263-275, 2000
117. Allen PG, Kolesar JM: NAD(P)H: Quinone oxidoreductase enhances proliferation inhibition by 4-hydroxytamoxifen. Anticancer Res 22:1475-1480, 2002
118. Phillips RM, Basu S, Brown JE, et al: Detection of (NAD(P)H: Quinone oxidoreductase-1, EC 1.6.99.2) 609C->T and 465C->T polymorphisms in formalin-fixed, paraffin-embedded human tumour tissue using PCR-RFLP. Int J Oncol 24:1005-1010, 2004
119. Ross D, Kepa JK, Winski SL, et al: NAD(P)H: quinone oxidoreductase 1 (NQO1): Chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 129:77-97, 2000
120. Kepa JK, Ross D: Differential expression of the antioxidant response element within the hNQO1 promoter in NSCLC versus SCLC. Biochem Biophys Res Commun 311:446-453, 2003
121. Kolesar JM, Pritchard SC, Kerr KM, et al: Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol 21:1119-1124, 2002
122. Basu S, Brown JE, Flannigan GM, et al: Immunohistochemical analysis of NAD(P)H: quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. Int J Cancer 109:703-709, 2004
123. Siegel D, Ross D: Immunodetection of NAD(P)H: quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 29:246-253, 2000
124. Wilson MW, Schelonka LP, Siegel D, et al: Immunohistochemical localization of NAD(P)H: quinone oxidoreductase in conjunctival melanomas and primary acquired melanosis. Curr Eye Res 22:348-352, 2001
125. Sarbia M, Bitzer M, Siegel D, et al: Association between NAD(P)H: Quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer 107:381-386, 2003
126. Siegel D, Gibson NW, Preusch PC, et al: Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50:7483-7489, 1990
127. Siegel D, Gibson NW, Preusch PC, et al: Metabolism of diaziquone by NAD(P)H: (quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50:7293-7300, 1990
128. Hoivik D, Wilson C, Wanf W, et al: Studies on the relationship between estrogen receptor content, glutathione S-transferase π expression, and induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin and drug resistance in human breast cancer cells. Arch Biochem Biophys 348:174-182, 1997
129. Bonnesen C, Eggleston IM, Hayes JD, et al: Dietary indols and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cancer cell lines. Cancer Res 61:6120-6130, 2001
130. Newcomb PA, Carbone PP: The health consequences of smoking. Med Clin North Am 76:305-331, 1992
131. Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review, 1973-1998. Bethesda, MD, National Cancer Institute, 2002
132. Huang ME, Ye YC, Chen SR, et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572, 1988
133. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
134. Gambacorti-Passerini C, Barni R, Marches: E, et al: Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease. Br J Haematol 112:972-974, 2001
135. Mahon FX, Deininger MW, Schultheis B, et al: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood 96:1070-1079, 2000
136. Lyseng-Williamson K, Jarvis B: Imatinib. Drugs 61:1765-1774, 2001
137. Kizaki M, Ueno H, Yamazoe Y, et al: Mechanisms of retinoid resistance in leukemic cells: Possible role of cytochrome P450 and P-glycoprotein. Blood 87:725-733, 1996
138. Renton KW: Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92:147-163, 2001
139. Morgan ET: Regulation of cytochrome p450 by inflammatory mediators: Why and how? Drug Metab Dispos 29:207-212, 2001
140. Slaviero KA, Clarke SJ, Rivory LP: Inflammatory response: An unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 4:224-232, 2003
141. Meredith CG, Christian CD, Johnson RE, et al: Effects of influenza virus vaccine on hepatic drug metabolism. Clin Pharmacol Ther 37:396-401, 1985
142. Dogra SC, Khanduja KL, Sharma RR: Hepatic drug-metabolising enzymes in lung tumour-bearing rats. Biochem Pharmacol 34:3190-3193, 1985
143. Chen G, Teicher BA, Frei E: Biochemical characterisation of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Cancer Biochem Biophys 16:139-155, 1998
144. Maliakal PP, Colville PF, Wanwimolruk S: Decreased hepatic drug metabolising enzyme activity in rats with nitrosamine-induced tumours. Drug Metabol Drug Interact 19:13-27, 2002
145. Bertilsson PM, Olsson P, Magnusson KE: Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells. J Pharm Sci 90:638-646, 2001
146. Philip PA, Kaklamanis L, Ryley N, et al: Expression of xenobiotic-metabolising enzymes by primary and secondary tumors in man. Int J Radiat Oncol Biol Phys 29:277-283, 1994
147. Rivory LP, Slaviero KA, Clarke SJ: Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 87:277-280, 2002
148. Miles JS, Mclaren AW, Forrester LM, et al: Identification of the human liver cytochrome P450 responsible for coumarin 7-hydroxylase activity. Biochem J 267:365-371, 1990
149. Paine AJ: The maintenance of cytochrome P-450 in rat hepatocyte culture: Some applications of liver cell cultures in the study of drug metabolism, toxicity and induction of the P-450 system. Chem Biol Interact 74:1-31, 1990
150. Antequara F, Boyes J, Bird A: High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 6:503-514, 1990
151. Rodriguez-Anotna C, Donato MT, Boobis A, et al: Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: Molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32:505-520, 2002
152. Hidalgo IJ, Bhatnagar P, Lee CP, et al: Structural requirements for interaction with the oligopeptide transporter in Caco-2 cells. Pharm Res 12:317-319, 1995
153. Yu LJ, Matias J, Scudiero DA, et al: P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos 29:304-312, 2001
154. Lu ZH, Zhang R, Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 267:17102-17109, 1992
155. Beck A, Etienne MC, Cheradame S, et al: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30:1517-1522, 1994
156. Nita ME, Tominaga O, Nagawa H, et al: Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer. Hepatogastroenterology 45:2117-2122, 1998
157. Etienne MC, Cheradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13:1663-1670, 1995
158. Danenberg K, Salonga D, Park CG, et al: Dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions identify a high percentage of colorectal tumors responding to 5-fluorouracil. Proc Am Soc Clin Oncol 17:258a, 1998 (abstr 992)
159. Ishikawa Y, Kubota T, Otani Y, et al: Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: Possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 91:105-112, 2000
160. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327, 2000
161. Iqbal S, Lenz H-J: Determinants of prognosis and response to therapy in colorectal cancer. Curr Oncol Rep 3:102-108, 2001
162. Royer I, Monsarrat B, Sonnier M, et al: Metabolism of docetaxel by human cytochromes P450: Interactions with paclitaxel and other anti-neoplastic drugs. Cancer Res 56:58-65, 1996
163. Miyoshi Y, Ando A, Takamura Y, et al: Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 97:129-132, 2002
164. Slatter JG, Su P, Sams JP, et al: Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 25:1157-1164, 1997
165. Iyer L, King CD, Whitington PF, et al: Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854, 1998
166. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
167. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
168. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
169. Xu Y, Villalona-Calero MA: Irinotecan: Mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13:1841-1851, 2002
170. Pavillard V, Charasson V, Laroche-Clary A, et al: Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan: A preliminary study. Anticancer Res 24:579-585, 2004
171. Tobin PJ, Dodds HM, Clarke S, et al: The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours. Oncol Rep 10:1977-1979, 2003
172. Xu G, Zhang W, Ma MK, et al: Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8:2605-2611, 2002
173. van Ark-Otte J, Kedde MA, van der Vijgh WJ, et al: Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer 77:2171-2176, 1998
174. Wu MH, Yan B, Humerickhouse R, et al: Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin Cancer Res 8:2696-2700, 2002
175. Cummings J, Ethell BT, Jardine L, et al: Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: Reversal of resistance by food additives. Cancer Res 63:8443-8450, 2003
176. Takahashi T, Fujiwara Y, Yamakido M, et al: The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. Jpn J Cancer Res 88:1211-1217, 1997
177. Cummings J, Boyd G, Ethell BT, et al: Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem Pharmacol 63:607-613, 2002
178. Cummings J, Zelcer N, Allen JD, et al: Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: Contribution of drug transport proteins. Biochem Pharmacol 67:31-39, 2004
179. Sladek NE: Aldehyde dehydrogenase-mediated cellular relative
180. Stoehlmacher J, Park DJ, Zhang W, et al: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936-942, 2002
181. Stanulla M, Schrappe M, Brechlin AM, et al: Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study. Blood 95:1222-1228, 2000
182. Krajinovic M, Labuda D, Mathonnet G, et al: Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 8:802-810, 2002
183. Sweeney C, Ambrosone CB, Joseph L, et al: Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 103:810-814, 2003
184. Yokoyama Y, Sato S, Fukushi Y, et al: Significance of multidrug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 25:387-394, 1999
185. Arai T, Yasuda Y, Takaya T, et al: Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small cell lung cancer. Cancer Detect Prev 24:252-257, 2000
186. Nishimura T, Newkirk K, Sessions RB, et al: Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer. Chem Biol Interact 111-112:187-198, 1998
187. Monden N, Abe S, Sutoh I, et al: Prognostic significance of the expression of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer. Oncology 54:391-399, 1997
188. Schisselbauer JC, Silber R, Papadopoulos E, et al: Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res 50:3562-3568, 1990
189. Tidefelt U, Elmhorn-Rosenborg A, Paul C, et al: Expression of glutathione transferase π as a predictor for treatment results at different stages of acute non-lymphoblastic leukemia. Cancer Res 52:3281-3285, 1992
190. Ghazal-Aswad S, Hogarth L, Hall AG, et al: The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients. Br J Cancer 74:468-473, 1996
191. Unsal M, Akpolat I, Kandemir B: Glutathione-S transferase expression in non-small cell lung cancer in the assessment of response to chemotherapy. Saudi Med 24:493-498, 2003
192. Ferrandina G, Scambia G, Damia G, et al: Glutathione S-transferase activity in epithelial ovarian cancer: Association with response to chemotherapy and disease outcome. Ann Oncol 8:342-350, 1997
193. Dhaini HR, Thomas DG, Giordano TJ, et al: Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 21:2481-2485, 2003
194. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097-4106, 2001
195. Hoff PM, Anasari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer. J Clin Oncol 19:2282-2292, 2001
196. Cassidy J, Scheithauer W, McKendrick J, et al: Capecitabine vs 5FU/leucovorin as adjuvant therapy for colon cancer (the X-ACT study): Efficacy of a phase III trial. Proc Amer Soc Clin Oncol 23:247s, 2004 (abstr 3509)
197. Budman DR, Meropol NJ, Reigner B, et al: Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 16:1795-1802, 1998
198. Twelves C, Boyer M, Findlay M, et al: Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal cancer. Eur J Cancer 37:597-604, 2001
199. Scheithauer W, McKendrick J, Begbie S, et al: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized phase III trial. Ann Oncol 14:1735-1743, 2003
200. Diasio RB: Current status of oral chemotherapy for colorectal cancer. Oncology (Huntingt) 15:16-20, 2001 (3 Suppl 5)
201. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237, 1989
202. Etienne MC, Pivot X, Formento JL, et al: A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 79:1864-1869, 1999
203. Baker SD, Peang Khor S, Adjei AA, et al: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14:3085-3096, 1996
204. Schilsky RL, Levin J, West WH, et al: Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 15:1519-1526, 2002
205. Van Cutsem E, Sorensen J, Cassidy J, et al: International phase III study of oral eniluracil plus 5-fluorouracil versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol 20:131a, 2001 (abstr 522)
206. Ohtsu A, Baba H, Sakata Y, et al: Phase II study of S-1, a novel oral fluoropyrimidine derivative in patients with metastatic colorectal carcinoma: S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83:141-145, 2000
207. Shirao K, Ohtsu A, Takada H, et al: Phase II study of S-1 for treatment of metastatic colorectal carcinoma. Cancer 100:2355-2361, 2004
208. Lyttle MH, Satyam A, Hocker MD, et al: Glutathione-S-transferase activates novel alkylating agents. J Med Chem 37:1501-1507, 1994
209. Morgan AS, Sanderson PE, Borch RF, et al: Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Res 58:2568-2575, 1998
210. Rosen LS, Brown J, Laxa B, et al: Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies. Clin Cancer Res 9:1628-1638, 2003
211. Brown GL, Lewis L, Choi H, et al: Phase I-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with liposomal doxorubicin in platinum refractory or resistant ovarian cancer. Proc Am Soc Clin Oncol 23:464s, 2004 (abstr 5062)
212. rd line) ovarian cancer. Proc Am Soc Clin Oncol 23:464s, 2004 (abstr 5060)
213. Papadimitrakopoulou V, Boasberg P, Figlin R, et al: Phase I-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer. Proc Am Soc Clin Oncol 23:651s, 2004 (abstr 7140)
214. Xu G, McLeod HL: Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 7:3314-3324, 2001
215. Evrard A, Cuq P, Ciccolini J, et al: Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer 80:1726-1733, 1999
216. Danks MK, Morton CL, Krull EJ, et al: Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 5:917-924, 1999
217. Lohr M, Hummel F, Faulmann G, et al: Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: The magic bullets of the 21st century. Cancer Chemother Pharmacol 49:S21-S24, 2002 (suppl 1)
218. Braybrooke JP, Slade A, Gibson R, et al: Phase I study of MetXia-450 therapy in patients with advanced breast cancer or melanoma. Proc Am Soc Clin Oncol 21:22a, 2002 (abstr 84)
219. Palmer DH, Mautner V, Mirza D, et al: Virus-directed enzyme prodrug therapy: Intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 22:1546-1552, 2004
220. James ND, Patel P, Mautner V, et al: A clinical trial of virus-directed enzyme prodrug therapy (VDEPT) using adenovirus encoded nitroreductase and CB1954 in patients with localized prostate cancer. Proc Am Soc Clin Oncol 23:399s, 2004 (abstr 4572)
221. Pedley RB, Sharma SK, Boxer GM, et al: Enhancement of antibody-directed enzyme pro-drug therapy in colorectal xenografts by an antivascular agent. Cancer Res 59:3998-4003, 1999
222. Guerquin-Kern JL, Volk A, Chenu E, et al: Direct in vivo observation of 5-fluorouracil release from a prodrug in human tumors heterotransplanted in nude mice: A magnetic resonance study. NMR Biomed 13:306-310, 2000
223. Napier MP, Sharma SK, Springer CJ, et al: Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 6:765-772, 2000
224. Webley SD, Francis RJ, Pedley RB, et al: Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material. Br J Cancer 84:1671-1676, 2001
225. Niculescu-Duvaz I, Spooner R, Marais R, et al: Gene-directed enzyme prodrug therapy. Bioconjug Chem 9:4-22, 1998
226. Syrigos KN, Epenetos AA: Antibody directed enzyme prodrug therapy (ADEPT): A review of the experimental and clinical considerations. Anticancer Res 19:605-613, 1999
227. Sawada N, Ishikawa T, Fukase Y, et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013-1019, 1998
228. Kurosumi M, Tabei T, Suemasu K, et al: Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 7:945-948, 2000
229. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002
230. Sawada N, Ishikawa T, Sekiguchi F, et al: X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5:2948-2953, 1999
231. Ngan S, Zalcberg J, Kell A, et al: Phase I study of capecitabine combined with radiotherapy for locally advanced potentially operable rectal cancer. Proc Am Soc Clin Oncol 20:149a, 2001 (abstr 591)
232. Ueda M, Kitaura K, Kusada O, et al: Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells. Jpn J Cancer Res 91:1185-1191, 2000
233. Metzger R, Danenberg K, Leichman CG, et al: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4:2371-2376, 1998
234. Petersen S, Thames HD, Nieder C, et al: The results of colorectal cancer treatment by p53 status: Treatment-specific overview. Dis Colon Rectum 44:322-333, 2001
235. Ramaswamy S, Golub TR: DNA microarrays in clinical oncology. J Clin Oncol 20:1932-1941, 2002
236. Emmert-Buck MR, Bonner RF, Smith PD, et al: Laser capture microdissection. Science 274:998-1001, 1996
237. Curran S, McKay JA, McLeod HL, et al: Laser capture microscopy. Mol Pathol 53:64-68, 2000
238. Mohr S, Bottin MC, Lannes B, et al: Microdissection, mRNA amplification and microarray: A study of pleural mesothelial and malignant mesothelioma cells. Biochimie 86:13-19, 2004
239. Yim SH, Ward JM, Dragan Y, et al: Microarray analysis using amplified mRNA from laser capture microdissection of microscopic hepatocellular precancerous lesions and frozen hepatocellular carcinomas reveals unique and consistent gene expression profiles. Toxicol Pathol 31:295-303, 2003
240. Schutze K, Lahr G: Identification of expressed genes by laser-mediated manipulation of single cells. Nat Biotechnol 16:737-742, 1998
241. Shekouh AR, Thompson CC, Prime W, et al: Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 3:1988-2001, 2003
242. Mohr S, Leikauf GD, Keith G, et al: Microarrays as cancer keys: An array of possibilities. J Clin Oncol 20:3165-3175, 2002
243. Kudoh K, Ramanna M, Ravatn R, et al: Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 60:4161-4166, 2000
244. Volas-Redd GH, Than C, Neish A, et al: The use of CDNA microarray to identify paclitaxel-induced changes in gene expression in non-small cell lung carcinoma cell lines. Proc Am Clin Oncol 19:503a, 2000 (abstr 1969)
245. Kang HC, Kim IJ, Park JH, et al: Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 10:272-284, 2004
246. Dan S, Tsunoda T, Kitahara O, et al: An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62:1139-1147, 2002
247. Mok SC, Chao J, Skates S, et al: Prostasin, a potential serum marker for ovarian cancer: Identification through microarray technology. Natl Cancer Inst 93:1458-1464, 2001
248. Gordon GJ, Jensen RV, Hsiao LL, et al: Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62:4963-4967, 2002
249. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
250. Chang JC, Woolen E, Elledge RM, et al: Gene expression profiles for docetaxel chemosensitivity. Proc Am Soc Oncol 21:426a, 2002 (abstr 1969)
251. Kikuchi T, Daigo Y, Katagiri T, et al: Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22:2192-2205, 2003
252. Erlander MG, Ellis MJ, Olson J, et al: Global gene expression profiling from formalin-fixed paraffin-embedded (FFPE) tissues; implications for retrospective and prospective clinical studies. Proc Am Soc Clin Oncol 22:125, 2003 (abstr 498)
253. Garrity MM, Burgart LJ, Mahoney MR, et al: Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: A North Central Cancer Treatment Group Study. J Clin Oncol 22:1572-1582, 2004
254. Allegra CJ, Paik S, Colangelo LH, et al: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21:241-250, 2003
255. Knoop AS, Bentzen SM, Nielsen MM, et al: Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19:3376-3384, 2001
256. Gambacorti-Passerini C, Barni R, le Coutre P, et al: Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92:1641-1650, 2000
257. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001
258. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004